Schizophrenia
Schizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.
TerminatedNCT06134661
Official study titleOptimizing rTMS for Psychomotor Slowing in Psychosis (ATMSSlowing) - A 1-week, Non-randomised Clinical Trial of add-on Accelerated Repetitive Transcranial Magnetic Stimulation for Psychomotor Slowing in Psychosis
This study ended early.
In BernSchizophreniaDevice studyAges 18–60
- Countries
- Switzerland
- Sponsor
- University of Bern
SuspendedNCT05567848
Official study titleAccelerated Transcranial Magnetic Stimulation in Psychotic Disorders
Recruitment is currently suspended.
In BostonSchizophreniaDevice studyAges 18–65
- Countries
- United States
- Sponsor
- Beth Israel Deaconess Medical Center
CompletedNCT03316664
This study has finished and is no longer accepting participants.
In ZurichSchizophreniaBehavioural studyAges 18–65
- Countries
- Switzerland
- Sponsor
- Psychiatric University Hospital, Zurich
CompletedNCT02504151
Official study titleCannabidiol Treatment in Patients With Early Psychosis
This study has finished and is no longer accepting participants.
Multiple locations, including New HavenSchizophreniaMedication studyAges 18–65
- Countries
- United States
- Sponsor
- Yale University
CompletedNCT02192593
Official study titleRandomized Controlled Trial of Computerized Cognitive Behavioral Therapy for Auditory Hallucinations in Persons With Psychosis
This study has finished and is no longer accepting participants.
In CambridgeSchizophreniaBehavioural studyAges 18–70
- Countries
- United States
- Sponsor
- Boston University Charles River Campus
CompletedNCT04429412
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaBehavioural studyAges 18–45
- Countries
- Sponsor
- Fundació Sant Joan de Déu
UnknownNCT05252039
Official study titleGoals in Focus: CBT for Motivational Negative Symptoms of Psychosis - a Randomized-controlled Feasibility Trial
Current recruitment status is unconfirmed.
In HamburgSchizophreniaBehavioural studyAges 16–85
- Countries
- Germany
- Sponsor
- University of Hamburg-Eppendorf
CompletedNCT02131116
Official study titleAn Integrated Metacognitive Approach to Improve Insight and Outcomes in Early Psychosis
This study has finished and is no longer accepting participants.
In IndianapolisSchizophreniaBehavioural studyAges 18–35
- Countries
- United States
- Sponsor
- Indiana University
TerminatedNCT00734435
Official study titleA Proof of Concept, Multi-Center, Randomized, Double-Blind, Parallel, Placebo-Controlled, Study of Zonisamide Sustained Release (SR) 360 mg Versus Placebo in the Prevention of Weight Gain Associated With Olanzapine Therapy for Psychosis
This study ended early.
Multiple locations, including National CitySchizophreniaMedication studyAges 18–55
- Countries
- United States
- Sponsor
- Orexigen Therapeutics, Inc
CompletedNCT02131129
Official study titleCortical Activation and Cognitive Performance During Repetitive Transcranial Magnetic Stimulation in First-Episode Psychosis: A Pilot Study
This study has finished and is no longer accepting participants.
In IndianapolisSchizophreniaDevice studyAges 18–40
- Countries
- United States
- Sponsor
- Indiana University
UnknownNCT06603922
Official study titleTowards a Personalized Medicine Approach to Psychological Treatment for Psychosis
Current recruitment status is unconfirmed.
Multiple locations, including ValparaísoSchizophreniaBehavioural studyAges 18–65
- Countries
- France, Chile, Germany, + 2 others
- Sponsor
- Polish Academy of Sciences
CompletedNCT00369239
Official study titleIs Premorbid Functioning a Predictor of Outcome in Patients With Early Onset Psychosis Treated With Risperdal Consta?
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18+
- Countries
- Sponsor
- Janssen Pharmaceutica N.V., Belgium